Hikma Pharmaceuticals PLC
2024 Annual General Meeting Update Statement
LONDON, 24 October 2024 - Hikma Pharmaceuticals PLC ('Hikma' or 'the Company'), the multinational pharmaceutical company, in accordance with the requirement of Provision 4 of the UK Corporate Governance Code, is providing an update following significant votes (defined as above 20%) against Resolution 22 ('the Rule 9 Waiver (Buyback Waiver)') at the Annual General Meeting ('AGM') held on 25 April 2024.
The Rule 9 Waiver (Buyback Waiver) sought the approval of independent shareholders for a waiver obtained from the Panel on Takeovers and Mergers in respect of any obligation that could arise, pursuant to Rule 9 of the Takeover Code, for the Darhold Concert Party (as defined in the 2024 Notice of AGM) to make a general offer for all the issued Ordinary Share capital of the Company, following an increase in the percentage of shares held by the Darhold Concert Party to 30% or more, resulting from the exercise by the Company of the authority to purchase its own Ordinary Shares pursuant to Resolution 20 (which received approval from 99.32% of those voting).
The Board believes that in order to promote the success of the Company and act in the best interests of shareholders, the Company should have the flexibility to return value to shareholders through a possible future buyback programme. Had the Rule 9 Waiver (Buyback Waiver) not been approved, the Company would not be able to effect such a buyback programme, as explained in the 2024 Notice of AGM.
The Company has continued to engage in a constructive dialogue with its shareholders and their proxy advisers following the AGM, to explain the rationale behind the Rule 9 Waiver (Buyback Waiver) and address any concerns they may have. The Company will provide further detail on these engagement activities in the 2024 Annual Report.
- ENDS -
Enquiries
| Hikma Pharmaceuticals PLC | |
| Helen Middlemist Group Company Secretary | +44 20 7399 2760 |
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI: 549300BNS685UXH4JI75)
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
